Attorneys and other experts told me that the two potential nominees for FDA commissioner, Jim O’Neill and Scott Gottlieb, both have publicly expressed ideas that would significantly change the way the agency operates.
O’Neill, a managing director at Mithril Capital Management, has said the FDA should approve drugs based solely on their safety and not, as the agency currently does, based on their safety and effectiveness. Meanwhile, Gottlieb, a resident fellow at the American Enterprise Institute (AEI), favors deregulation and loosening the agency’s requirements for the approval of medical products.
Gottlieb is the more experienced candidate, having worked at the agency as a deputy commissioner and also having a medical degree, attorneys told me. But the fact that both candidates have ties to FDA-regulated industries should disqualify them, Michael Carome, director of Public Citizen’s Health Research Group, told me.
Gottlieb served as FDA deputy commissioner for medical and scientific affairs from 2005 to 2007. In addition to being a resident fellow at the AEI, Gottlieb is a venture partner at New Enterprise Associates, a firm that invests in medical and life sciences companies. AEI is a nonpartisan public policy research institute.
O’Neil’s firm Mithril Capital Management has invested in the medical device company Fractyl Laboratories Inc. It also invested in Avitide Inc., a manufacturer of purification solutions for the biopharmaceutical industry. O’Neill last served in government during the George W. Bush administration as principal associate deputy secretary at the Department of Health and Human Services.
My full story is at https://www.bna.com/potential-picks-lead-n73014448800/.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)